AstraZeneca CEO urges western drugmakers to adopt 'Chinese speed'

AstraZeneca's chief executive, Pascal Soriot, has warned that Western drugmakers must accelerate their innovation to match the pace of their Chinese counterparts, or risk falling behind as the Western automotive industry did. Soriot emphasized the need for the pharmaceutical sector in the US and Europe to operate at "Chinese speed" to remain competitive globally.

The warning comes as AstraZeneca, a FTSE 100 company, closely monitors the rapid rise of China's pharmaceutical industry. The company is actively collaborating with Chinese firms to bring new drugs to international markets, but Soriot stressed that Western companies must increase their innovation speed to avoid being outpaced.

This matters because the global pharmaceutical landscape is shifting, with China emerging as a major player in drug development. If Western companies fail to adapt, they could lose their competitive edge, similar to how the Western automotive industry lost ground to Asian manufacturers. Soriot's remarks highlight the urgency for Western drugmakers to streamline processes and embrace faster innovation cycles.

AstraZeneca has been working with Chinese partners to develop and commercialize drugs, leveraging China's growing expertise and efficiency. The company's strategy includes co-developing treatments for global markets, which allows it to benefit from China's accelerated timelines. However, Soriot cautioned that this collaboration alone is not enough; Western companies must fundamentally change their approach to innovation.

Looking ahead, Soriot's comments suggest that Western pharmaceutical companies may need to adopt more agile research and development models, potentially restructuring their operations to speed up drug discovery and approval processes. The outcome could reshape the industry's global dynamics, with implications for drug availability and pricing worldwide.